


## Total Synthesis and Cytoprotective Properties of Dykellic Acid

Christina M. Thompson, Catherine A. Quinn, and Paul J. Hergenrother

*J. Med. Chem.*, **2009**, 52 (1), 117-125 • DOI: 10.1021/jm801169s • Publication Date (Web): 10 December 2008

Downloaded from <http://pubs.acs.org> on January 5, 2009



### More About This Article

Additional resources and features associated with this article are available within the HTML version:

- Supporting Information
- Access to high resolution figures
- Links to articles and content related to this article
- Copyright permission to reproduce figures and/or text from this article

[View the Full Text HTML](#)



**ACS Publications**  
High quality. High impact.

## Total Synthesis and Cytoprotective Properties of Dykellic Acid

Christina M. Thompson, Catherine A. Quinn, and Paul J. Hergenrother\*

Department of Chemistry, Roger Adams Laboratory, University of Illinois, Urbana, Illinois 61801

Received September 17, 2008

Small molecule inhibitors of apoptosis hold considerable promise for the treatment of a host of diseases, including neurodegeneration, myocardial infarction, and stroke. Many compounds that delay or prevent apoptotic death either reduce the amount of cellular reactive oxygen species (ROS) or are direct inhibitors of caspases. With the goal of using small molecules to identify novel antiapoptotic targets, we have investigated the cytoprotective activity of the natural product dykellic acid. Described herein is the first total synthesis of dykellic acid, the synthesis of several dykellic acid derivatives, and the evaluation of these compounds in assays related to cell death. We have found that dykellic acid protects cells from death as induced by etoposide and rotenone. Further experiments strongly suggest that dykellic acid does not scavenge ROS or directly inhibit caspase enzymes, and analysis of synthetic derivatives establishes key functional groups of the molecule that are essential for its cytoprotective activity.

### Introduction

Apoptosis is an energy-dependent pathway used by higher eukaryotes to selectively remove damaged or unwanted cells. The misregulation of this pathway has negative consequences for the organism, as abnormally low levels of apoptosis allow cells to proliferate unchecked and elevated levels of apoptosis can damage healthy tissue. As such, compounds that modulate apoptosis have great potential as therapeutics.<sup>1</sup> Specifically, inducers of apoptosis can be powerful anticancer agents,<sup>2</sup> and compounds that inhibit apoptosis could be useful in the treatment of neurodegeneration,<sup>3</sup> sepsis,<sup>4</sup> osteoarthritis,<sup>5</sup> myocardial infarction,<sup>6</sup> ischemic injury/stroke,<sup>7</sup> and many other disease states where cytoprotection is sought.

Apoptosis is classically believed to be initiated through one of two major pathways: (1) the intrinsic pathway that involves the mitochondria; (2) the extrinsic pathway in which apoptosis is initiated through death receptors on the cell surface. The intrinsic pathway can be stimulated by DNA damaging agents or other insults that generate reactive oxygen species (ROS<sup>a</sup>),<sup>8</sup> while death through the extrinsic pathway is initiated by a host of death receptor ligands including FasL and TNF $\alpha$ .<sup>9</sup> There is considerable cross-talk between these pathways; thus, most proapoptotic signals ultimately lead to the release of apoptogenic factors from the mitochondria.<sup>10</sup> Both the intrinsic and extrinsic pathways funnel to the activation of caspases, cysteine proteases that cleave a multitude of cellular substrates and execute the cell death program.<sup>11</sup>

Targeted approaches to the inhibition of apoptosis that have focused on the scavenging of ROS or the inhibition of caspases have revealed that these strategies can effectively halt apoptosis in certain cell culture models.<sup>12,13</sup> Unfortunately, large retrospective studies have shown that individuals taking high doses


of the antioxidant vitamin E have no increase in life span.<sup>14</sup> In addition, the recent failure of free radical scavenger disufenton sodium (NXY-059) in large clinical trials for treatment of stroke has led to a rethinking of the manner in which neuroprotection clinical trials are performed,<sup>15</sup> although certainly some antioxidants may still hold promise as therapeutics.<sup>16</sup> Multiple potent caspase inhibitors are available,<sup>17</sup> and both caspase-1 inhibitors and pan-caspase inhibitors are being evaluated in clinical trials for arthritis, liver disease, and protection of organs during transplant.<sup>18</sup> However, there is some concern that inhibition of caspases may be too late in the apoptotic pathway to prevent cellular demise.<sup>19</sup> In this school of thought, the “point of no return” for apoptotic cell death is believed to be much earlier than caspase activation, likely depolarization of the mitochondrial membrane and the concomitant release of proapoptotic proteins.<sup>20</sup> By this logic, for an antiapoptotic agent to have maximal therapeutic benefit it would need to work upstream of caspase activation.

As a means to discover novel antiapoptotic targets, we sought to identify cytoprotective agents that operate through mechanisms not based on the scavenging of ROS or the direct inhibition of caspases. In this regard, dykellic acid (**1**, Scheme 1), a product of the fermentation broth of soil fungus *Westerdykella multispora*, attracted our attention because of its compact, densely functionalized structure and its reported ability to inhibit etoposide-induced apoptosis in HL-60 (human leukemia) cells.<sup>21</sup> Other interesting biological properties of dykellic acid have been described, including its ability to inhibit cell migration<sup>22</sup> and interfere with NF- $\kappa$ B transcriptional activity.<sup>23</sup> Dykellic acid has also been reported to decrease the overall caspase-3-like activity in cells treated with camptothecin,<sup>24</sup> though on the basis of its structure, it seems unlikely that dykellic acid is a direct caspase inhibitor. We thus set out to synthesize dykellic acid, assess its protective effects in several cell culture models of apoptosis, and conduct experiments designed to clarify its mechanism of action.

Described herein is the first total synthesis of dykellic acid, the synthesis of several dykellic acid derivatives, and the biological evaluation of these compounds. Our results show that dykellic acid strongly protects cells from apoptosis as induced by two distinct proapoptotic stimuli, etoposide and rotenone. On the basis of the evaluation of dykellic acid derivatives, it

\* To whom correspondence should be addressed. Phone: 217-333-0363. Fax: 217-244-8024. E-mail: hergenro@uiuc.edu.

<sup>a</sup> Abbreviations: ROS, reactive oxygen species; HWE, Horner–Wadsworth–Emmons; MBH, Morita–Baylis–Hillman; MNNG, *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine; TNF $\alpha$ , tumor necrosis factor  $\alpha$ ; PARP-1, poly-(ADP-ribose)polymerase-1; Z-VAD-fmk, Cbz-VAD-fluoromethyl ketone; pNA, *p*-nitroaniline; H<sub>2</sub>DCF, 2,7-dichlorodihydrofluorescein; DHE, dihydroethidium; DCF, 2,7-dichlorofluorescein; TACE, tumor necrosis factor  $\alpha$  converting enzyme; MMP, matrix metalloproteinases; SDM, standard deviation from the mean.

**Scheme 1.** Retrosynthetic Analysis of Dykellic Acid

appears that the diene side chain and the carboxylic acid moiety are critical to the cytoprotective effect of dykellic acid. Further, dykellic acid does not inhibit caspases *in vitro* nor does it scavenge ROS in cells. These data imply that dykellic acid exerts its antiapoptotic effect through an alternative mechanism, one that allows it to protect cells from diverse proapoptotic stimuli.

**Results and Discussion**

**Retrosynthetic Analysis.** A concise and flexible route to dykellic acid was desired to allow synthesis of both the parent natural product and a series of analogues. In the retrosynthetic analysis (Scheme 1), two key carbon–carbon bond forming reactions were envisioned: a Horner–Wadsworth–Emmons (HWE) reaction to unite aldehyde 2 with phosphonate 3 and a Morita–Baylis–Hillman (MBH) reaction between 2,4-hexadienal (4) and methyl acrylate (5). The Still modification of the HWE olefination was chosen because of the reliable *Z*-selectivity it offers in the formation of the desired trisubstituted double bond,<sup>25</sup> while the MBH reaction is a facile method for the formation of allylic alcohols;<sup>26,27</sup> as applied in Scheme 1, this reaction would allow for the assembly of a large fragment of dykellic acid in a single step. As dykellic acid was isolated from *Westerdykella multisporea* as the racemate,<sup>21</sup> no attempt was made to synthesize the compound as a single enantiomer.

**Total Synthesis of Dykellic Acid.** The MBH reaction creates new carbon–carbon bonds between  $\alpha,\beta$ -unsaturated esters,<sup>28</sup> amides,<sup>29</sup> and nitriles,<sup>30</sup> and appropriate aldehyde electrophiles. This method is most suited to alkylaldehydes and arylaldehydes, though there is some precedent for  $\alpha,\beta$ -unsaturated aldehydes.<sup>31</sup> When  $\alpha,\beta$ -unsaturated aldehydes are utilized in the MBH reaction, longer reaction times and lower yields (relative to their saturated counterparts) are typically observed.<sup>27</sup> As the first step toward the synthesis of dykellic acid, 2,4-hexadienal (4) and methyl acrylate (5) were used as partners for the MBH reaction (Scheme 2). After a variety of temperatures, times, and tertiary amines were screened, it was determined that the reaction proceeded best at 0 °C for 3 days in the presence of 1,4-diazabicyclo[2.2.2]octane (DABCO), generating alcohol 7 in

70% yield; this reaction has been performed on as much as a 72 g (0.75 mol) scale. Longer reaction times did not significantly improve the yield, while temperatures above 0 °C led to increased amount of side products. To the best of our knowledge 2,4-hexadienal has not previously been used in the MBH reaction. Commercial 2,4-hexadienal is provided as a mixture of *trans,trans* and *trans,cis* isomers (about 85:15, respectively), leading to a corresponding mixture of isomers in the product. As shown in Scheme 3, independent synthesis of isomerically pure *trans,trans*-2,4-hexadienal (4a) from *trans,trans*-2,4-hexadienol<sup>32</sup> followed by the MBH reaction with methyl acrylate also provided alcohol 7 as an isomeric mixture, presumably because of unproductive 1,6 addition of DABCO to the aldehyde.

Alcohol 7 was converted to its triethylsilyl ether 8 in 95% yield before being subjected to reduction by DIBAL-H, which provided alcohol 9 in 80% yield (Scheme 2). At this time the *trans,cis* isomer of 9 was removed by chromatography with 25% AgNO<sub>3</sub>-impregnated silica gel.<sup>33</sup> Loading 1 g of alcohol 9 onto 100 g of AgNO<sub>3</sub>-impregnated silica gel yielded 35% pure isomer 9a and 50% of isomerically impure alcohol 9, which could be purified again through this procedure. Repeating this process several times afforded an overall yield of 55% of 9a. After this separation, isomerically pure 9a was oxidized using Dess–Martin periodinane<sup>34</sup> to provide aldehyde 10 in 79% yield (Scheme 2).



In preparation for the key olefination, phosphonate 3 was synthesized as shown in Scheme 4. Commercially available 1-bromo-3-propanol was protected as its *tert*-butyldimethylsilyl ether, which was then subjected to Finkelstein's conditions to exchange the bromide for an iodide. Iodide 11 was subsequently used to alkylate hexafluorodiethyl phosphonate 6, providing target phosphonate 3 in 86% yield.

With both main subunits of dykellic acid in hand, attention was turned to the critical HWE reaction. In an effort to obtain the desired *Z*-olefin, Still's modification of the HWE reaction was utilized. Initially, aldehyde 2 (generated from an acid-catalyzed deprotection of 10) was used as the substrate in the HWE reaction with phosphonate 3 (Scheme 5, eq 1). It was envisioned that olefination would be followed by rapid intramolecular cyclization to provide lactone 12. Unfortunately, under a variety of reaction conditions (bases, solvents, additives, temperatures), the reaction between 2 and 3 produced only very low (<15%) yields of the desired product (Scheme 5, eq 1). However, utilization of the TES-protected substrate 10 in this reaction provided the trisubstituted olefin 13 in 58% yield with a *Z/E* ratio (around the new double bond) of 10:1 (Scheme 5, eq 2).


With the final carbon–carbon bond in place, the two silyl ether protecting groups of 13 were removed using an AcOH/H<sub>2</sub>O mixture, which also catalyzed the spontaneous cyclization to the desired lactone 14 (Scheme 6). Lactone 14 was found to be unstable and was thus immediately oxidized to aldehyde 15 using Dess–Martin periodinane. Treatment of aldehyde 15 with sodium chlorite<sup>35</sup> furnished dykellic acid (1) in a 60% yield. The spectroscopic data for this synthetic dykellic acid match the data of the isolated natural product<sup>21</sup> in all respects (see Supporting Information).

**Synthesis of Dykellic Acid Derivatives.** With a synthetic route to dykellic acid in place, derivatives in which various functional groups were systematically deleted/alterd were synthesized. These derivatives (shown in Figure 1) were designed to probe the relationship of compound structure to biological activity. Specifically, the importance of the diene side


## Scheme 2. Synthesis of Aldehyde 10

Scheme 3. Reaction of Isomerically Pure *trans,trans*-2,4-Hexadienal with Methyl Acrylate under the MBH Conditions Provides a Mixture of Product Isomers

## Scheme 4. Synthesis of Phosphonate 3



## Scheme 5. Olefination of Aldehydes 2 and 10



chain and the pendent acid were probed through the synthesis and evaluation of compounds **16**–**23**.

The carboxylic acids in **1** and **18** were converted to the corresponding methyl esters using trimethylsilyldiazomethane (TMSCHN<sub>2</sub>), producing derivatives **16** and **22**, respectively. Derivatives **17** and **18** were synthesized by following the same route to **1** but with substitution of 2,4-hexadienal with hex-2-enal or hexanal in the first step of the synthesis. Lactones **20**, **21**, and **23** (lacking the carboxylic acid side chain) were produced through a HWE reaction with phosphonate **6** and the appropriate aldehyde (see Supporting Information for full routes and details).


**Cytoprotective Effects of Dykellic Acid.** To define the generality of the cytoprotective effect of dykellic acid, this compound was evaluated in several different cell culture models

of cell death. These models consisted of pretreatment of U-937 (human lymphoma cell line) cells with dykellic acid for 5 h, followed by application of a cellular insult and measurement of cell death after 24 h by propidium iodide staining and cell flow cytometry. U-937 cells are a promonocytic cell line that grows rapidly as a suspension (nonadherent) in tissue culture flasks and are commonly used in cytoprotection assays.<sup>36–38</sup>

The ability of dykellic acid to protect U-937 cells from a diverse array of cellular insults was explored through the use of rotenone (a mitochondrial complex I inhibitor that induces apoptosis<sup>39</sup> and is commonly used in cell culture models of Parkinson's disease<sup>40</sup>), etoposide (a proapoptotic topoisomerase inhibitor and anticancer chemotherapeutic utilized as a cell culture model of damage induced by chemotherapeutics),<sup>41</sup> H<sub>2</sub>O<sub>2</sub> (induces necrotic cell death and used as a model of oxidative damage),<sup>42</sup> and *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine (MNNG) (a DNA alkylating agent that can induce a variety of types of cell death).<sup>43,44</sup>

For these experiments, U-937 cells were incubated with a range of dykellic acid concentrations for 5 h and then subjected to the various toxins. After 24 h, the viability of the U-937 cells was assessed by propidium iodide staining and cell flow cytometry. The level of protection observed is expressed as percent protection, calculated from the percent of cells alive when compared to control cells treated with either vehicle alone or toxin alone (for more details, see the Supporting Information). As shown by the graphs in Figure 2, dykellic acid is able to protect cells in a dose-dependent fashion from etoposide- and rotenone-induced cell death. Interestingly, dykellic acid is only minimally protective against MNNG-induced cell death and not protective against H<sub>2</sub>O<sub>2</sub>-induced cell death (see Supporting Information for graphs).

**Cytoprotective Effects of Dykellic Acid Derivatives.** The various dykellic acid derivatives synthesized (Figure 1) were evaluated for their ability to protect U-937 cells from etoposide-induced cell death. As shown in Figure 3, compound **19**, the isomerically impure form of dykellic acid, is as protective as **1**. Removal of the  $\gamma,\delta$ -unsaturation from the diene chain (**17**) provides a compound that remains protective, whereas the compound with the diene side chain fully saturated (**18**) has no protective effect. All compounds in which the carboxylic acid is modified (**16** and **22**), or removed entirely (**20**, **21**, and **23**) are not protective, and in fact some of these compounds are toxic to U-937 cells (see Supporting Information). From the data, it appears that minimally the  $\alpha,\beta$ -unsaturation in the diene side chain and the carboxylic acid functionality of dykellic acid are critical to its cytoprotective properties.


**Scheme 6.** Deprotection, Cyclization, and Oxidation Provides Dykellic Acid

**Dykellic Acid Reduces Cellular Levels of Caspase-3/-7 Activity.** Caspases are cysteine proteases that are key players in the cascade of events leading to apoptotic death.<sup>45</sup> Caspases exist in the cell as low activity zymogens (procaspases) that are activated in response to a variety of proapoptotic signals. Caspases-8 and -9 are initiator caspases that directly catalyze the hydrolysis of procaspase-3 and -7, converting them to the active executioner caspases, caspases-3 and -7.<sup>46</sup> Once activated, these enzymes then cleave a variety of cellular substrates. A common means to assess apoptotic death is through the measurement of caspase-3/-7 activity in the lysate of cells that have been treated with a proapoptotic agent.<sup>47</sup> Thus, as an initial experiment to determine the mechanism by which dykellic acid exerts its cytoprotective effect, U-937 cells were pretreated with a range of dykellic acid concentrations for 5 h and then treated with etoposide (to a final concentration of 1.5  $\mu\text{M}$ ) for 24 h. After 24 h the cells were lysed and the amount of caspase-3/-7 activity was determined by monitoring the cleavage of the peptidic substrate Ac-DEVD-pNA. Active caspase enzymes catalyze the hydrolytic release of *p*-nitroaniline (pNA) from this substrate, a reaction that can conveniently be monitored at 405 nm. A control with the pan-caspase inhibitor Cbz-VAD-fluoromethyl ketone (Z-VAD-fmk)<sup>17</sup> was also included in the experiment. As shown in Figure 4, caspase activity is not detectable in the lysates from Z-VAD-fmk treated cells, and high concentrations of dykellic acid also significantly reduce the amount of cellular caspase activity in this assay.


**Dykellic Acid Is Not a Direct Inhibitor of Caspase-3, -6, -7, or -8.** One means by which compounds can delay cell death is through direct inhibition of caspases. The vast majority of caspase inhibitors are peptidic in nature,<sup>48</sup> although small

molecule caspase inhibitors are also known.<sup>49</sup> The data presented in Figure 4 indicate that dykellic acid exerts its cytoprotective effect either by inhibiting an upstream cascade that leads to caspase activation or through direct inhibition of caspases. To test whether dykellic acid itself directly inhibits caspases *in vitro*, full Michaelis–Menten (velocity vs [substrate]) curves were obtained for recombinantly expressed and purified caspases-3, -6, -7, and -8 in the presence of various concentrations of dykellic acid (see Supporting Information for full curves). The enzymes' activity was assessed by monitoring the caspase-mediated hydrolytic release of *p*-nitroaniline (pNA) from tetrameric peptide substrates specific for each enzyme.<sup>50</sup> Thus, the Ac-DEVD-pNA substrate was used for caspase-3 and -7, Ac-VEID-pNA was used for caspase-6, and Ac-IETD-pNA was used for caspase-8. The data from these experiments show that dykellic acid has no effect on the ability of these caspases to process their substrate *in vitro*, even up to dykellic acid concentrations of 100  $\mu\text{M}$ . For example, we measured the  $k_{\text{cat}}/K_{\text{M}}$  values for caspase-3, -6, -7, -8 as 308, 245, 80, and 38  $\text{M}^{-1} \text{s}^{-1}$ , respectively; in the presence of 100  $\mu\text{M}$  dykellic acid we obtained similar values of 292, 246, 78, and 41  $\text{M}^{-1} \text{s}^{-1}$ , respectively. Hence, dykellic acid is not an inhibitor of caspase-3, -6, -7, or -8 *in vitro* and is unlikely to be a direct inhibitor of any of the caspase enzymes.

**Effect of Dykellic Acid on Levels of Cellular ROS.** General antioxidants are often cytoprotective because of the central role of ROS in mitochondria-mediated apoptosis.<sup>13</sup> We therefore sought to establish if dykellic acid acts directly as a ROS scavenger in cells. Two different ROS sensitive dyes were employed for this assay, 2,7-dichlorodihydrofluorescein ( $\text{H}_2\text{DCF}$ ) and dihydroethidium (DHE).  $\text{H}_2\text{DCF}$  is converted to 2,7-dichlorofluorescein (DCF) in the presence of intracellular



**Figure 1.** Derivatives of dykellic acid.



**Figure 2.** Dykellic acid protects cells against two different types of insult. U-937 cells were treated with dykellic acid for 5 h before (A) etoposide was added to a final concentration of 1.5  $\mu\text{M}$  or (B) rotenone was added to a final concentration of 5  $\mu\text{M}$ . Cell death was assessed 24 h later by propidium iodide staining and cell flow cytometry. Error bars represent SDM from  $n = 3$ , with each trial performed in triplicate.

peroxides,<sup>51</sup> whereas DHE provides a sensitive readout on intracellular levels of superoxide radicals through oxidation by superoxide anion radicals to form ethidium.<sup>52</sup> U-937 cells were treated with dykellic acid at varying concentrations for 5 h, after which time rotenone was added and the levels of cellular ROS were measured.  $\alpha$ -Tocopherol, a well established antioxidant,<sup>53</sup> was used as a positive control. As shown in Figure 5,  $\alpha$ -tocopherol significantly decreases ROS levels in rotenone-treated cells (as measured by the fluorescence of both DCF and ethidium). However, dykellic acid had no effect in this assay, even at concentrations of 100  $\mu\text{M}$ , strongly suggesting that dykellic acid does not alter intracellular levels of ROS.

## Discussion


The data presented herein show that dykellic acid protects U-937 cells from death as induced by rotenone and etoposide. Although cells treated with dykellic acid show markedly reduced levels of caspase-3/-7-like activity, our data indicate that dykellic acid is not a direct inhibitor of caspase-3, -6, -7, or -8 *in vitro*, suggesting that the compound acts to suppress caspase activation in some upstream portion of the apoptotic cascade. As ROS is a key player in apoptotic induction, we examined the effect of dykellic acid on ROS production. Interestingly, the levels of intracellular ROS were not altered in the presence of dykellic acid. The fact that dykellic acid does not appear to directly

quench cellular ROS is also consistent with the inability of this compound to protect against  $\text{H}_2\text{O}_2$ -induced cell death, as  $\text{H}_2\text{O}_2$ -treatment results in the direct and rapid generation of cellular ROS.<sup>54</sup> Thus, the combined data suggest that dykellic acid exerts its cytoprotective effect on cells in culture through some less common mechanism, one not involving direct caspase inhibition or ROS-scavenging.


The protective properties of dykellic acid were evaluated against four different toxins: etoposide, rotenone, MNNG, and hydrogen peroxide. Etoposide inhibits topoisomerase II, a phosphodiesterase that catalyzes the hydrolysis of double stranded DNA, allowing relaxation of supercoiled DNA. By preventing topoisomerase II from re-ligating the double strand break, etoposide turns topoisomerase II into a destructive DNA cleaving enzyme.<sup>55</sup> While the pathway between etoposide-induced DNA damage and apoptotic induction is not entirely understood, caspase-2, -3, and -8 have been shown to be important links for stimulation of the mitochondrial apoptotic pathway and the execution of apoptosis.<sup>56</sup> The pesticide rotenone is a potent inhibitor of complex I, an enzyme in the mitochondrial electron transport chain. This inhibition in turn causes the production of ROS, which causes cellular stress and ultimately leads to death, again through an apoptotic pathway in U-937 cells.<sup>39,57</sup>

The other two toxins tested, MNNG and  $\text{H}_2\text{O}_2$ , are fundamentally different from etoposide and rotenone in that in U-937 cells they cause mainly caspase independent cell death or necrosis. MNNG is a DNA alkylating agent that causes caspase-independent cell death through poly(ADP-ribose)polymerase-1 (PARP-1) activation.<sup>58</sup> Upon DNA alkylation PARP-1 is activated, inducing synthesis of the toxic poly(ADP-ribose) biopolymer<sup>59</sup> and causing depletion of cellular energy stores, both of which lead to rapid death without the activation of caspase enzymes.<sup>60</sup> Hydrogen peroxide has been shown to induce necrotic death in U-937 cells.<sup>61</sup> When hydrogen peroxide is added to cells, peroxide radicals oxidize not only DNA but also proteins and lipids, starting a host of enzymatic cascades that lead to cell death.<sup>35,37</sup>

Comparing the mechanisms of these toxins allows some conclusions to be drawn about how dykellic acid might be protecting cells from death. Dykellic acid is most protective against the toxins that effect cell death through caspase-dependent apoptosis, specifically through the mitochondria, and is less protective against those that cause necrotic cell death/caspase-independent cell death. On the basis of the data presented herein, we postulate that dykellic acid inhibits apoptosis at some point between the ROS-mediated initiation of apoptosis and caspase activation. Importantly, by inhibiting cell death before activation of the executioner caspases, dykellic acid has the potential to protect cells before they have passed the "point of no return" down the cell death pathway, although it remains to be seen if dykellic acid acts on targets upstream or downstream of mitochondria membrane depolarization. Compounds that inhibit apoptosis by acting on targets before caspase activation have intriguing potential as therapeutic agents. Although small molecules that inhibit apoptosis without directly affecting cellular ROS levels or caspase activity are less common, they are not without precedent; for example, geldanamycin and herbimycin A inhibit death in U-937 cells through induction of Hsp70 synthesis,<sup>36,62</sup> and small molecule inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1) are known to be protective in certain cell culture and animal models of neurodegeneration and stroke.<sup>63</sup>



**Figure 3.** An intact diene side chain is essential to the full cytoprotective activity of dykellic acid. Cells were treated with compound **18**, **19**, or **20** for 5 h before etoposide was added to a final concentration of 1.5  $\mu\text{M}$ . Cell death was assessed 24 h later by propidium iodide staining and cell flow cytometry. Error bars represent SDM from  $n = 3$ , with each trial performed in triplicate.




**Figure 4.** Dykellic acid reduces caspase-3/-7-like activity in etoposide-treated cells. U-937 cells were treated with Z-VAD-fmk (100 nM) or varying concentrations of dykellic acid for 5 h, and etoposide was then added to a final concentration of 1.5  $\mu\text{M}$ . After 24 h the cells were transferred to caspase assay buffer and lysed, and the caspase substrate Ac-DEVD-pNA was added to a final concentration of 200  $\mu\text{M}$ . The amount of pNA produced per minute was measured at 405 nm. All wells contained 1% of the vehicle, DMSO. The caspase-3/-7-like activity of cells treated with vehicle plus etoposide was normalized to 1.0, while the activity of cells treated with just vehicle (not shown) was normalized to 0. Error bars represent SDM from a single experiment performed in triplicate; these data are representative of three experiments. Statistical significance relative to vehicle control is indicated: (\*)  $P < 0.02$ ; (\*\*)  $P < 0.001$ .

The structure–activity relationship established through synthesis and evaluation of dykellic acid derivatives provides insights into the mode of action of this compound and suggests opportunities for the enhancement of efficacy. Given the importance of the  $\alpha,\beta$ -unsaturation in the diene side chain to its cytoprotective activity and the preponderance of electrophilic sites on dykellic acid, a key outstanding question is whether dykellic acid is covalently modifying its biological target. However, the  $\delta,\gamma$ -double bond of the diene side chain can be eliminated with minimal loss of activity, suggesting that chemical modifications could be made to this side chain in an effort to improve biological activity or to identify the cellular target. With a tractable and flexible route dykellic acid in place, such studies are now feasible. Members of the gelastatin family of natural products are structurally related to dykellic acid.

Gelastatins and some derivatives have been reported as inhibitors of matrix metalloproteinases (MMP) and tumor necrosis factor  $\alpha$  converting enzyme (TACE),<sup>64</sup> and dykellic acid itself is known to inhibit the expression and activity of MMP-9 in cells.<sup>23</sup> Whether or not there is a direct connection between this MMP inhibition and dykellic acid's cytoprotective effect, at this point, is unclear.

In summary, we have achieved the first total synthesis of dykellic acid through an efficient and flexible route whose longest linear sequence is eight chemical steps from commercially available starting materials. As shown herein, dykellic acid protects U-937 cells from cellular insults that induce caspase-dependent apoptosis but is minimally protective against insults that induce other forms of cell death. Interestingly, this cytoprotection is mediated through neither the scavenging of



**Figure 5.** Dykellic acid does not quench intracellular reactive oxygen species. U-937 cells were treated with  $\alpha$ -tocopherol (100  $\mu$ M) or a range of dykellic acid concentrations for 5 h, at which point rotenone was added to a final concentration of 20  $\mu$ M. After 40 min dihydroethidium or dichlorodihydrofluorescein diacetate ( $H_2DCF$ ) was added and cellular fluorescence was assessed by cell flow cytometry. The 5, 10, 50, and 100  $\mu$ M dykellic acid data points are not statistically different from the vehicle plus rotenone control. Statistical significance versus rotenone treated vehicle control is noted: (\*)  $P < 0.016$ . Error bars represent SDM from  $n = 3$ , with each trial performed in triplicate.

cellular ROS nor the direct inhibition of caspases. The structure–activity relationship established through the synthesis of key dykellic acid derivatives sets the stage for the optimization of dykellic acid's cytoprotective activity and for studies aimed at identifying the precise biological target of this compound. There are a multitude of disorders caused by premature cell death; dykellic acid's potency and nonstandard mechanism of cytoprotection make it an interesting candidate for evaluation in models of these disease states.

**Acknowledgment.** We thank Margaret Wong for performing initial experiments directed toward the synthesis of **10**. This research was supported by the University of Illinois, Urbana–Champaign, and by the Alfred P. Sloan Foundation (Sloan Foundation Fellowship to P.J.H.).

**Supporting Information Available:** Materials and methods, NMR spectra of all new compounds, and supporting figures. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## References

- Alam, J. J. Apoptosis: target for novel drugs. *Trends Biotechnol.* **2003**, *21*, 479–483.
- (a) Makin, G.; Dive, C. Recent advances in understanding apoptosis: new therapeutic opportunities in cancer chemotherapy. *Trends Mol. Med.* **2003**, *9*, 251–255. (b) Meng, X. W.; Lee, S. H.; Kaufmann, S. H. Apoptosis in the treatment of cancer: a promise kept? *Curr. Opin. Cell Biol.* **2006**, *18*, 668–676.
- (a) Pattison, L. R.; Kotter, M. R.; Fraga, D.; Bonelli, R. M. Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease. *J. Neurol.* **2006**, *253*, 1137–1142. (b) Vila, M.; Przedborski, S. Targeting programmed cell death in neurodegenerative diseases. *Nat. Rev. Neurosci.* **2003**, *4*, 365–375. (c) Waldmeier, P. C. Prospects for antiapoptotic drug therapy of neurodegenerative diseases. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2003**, *27*, 303–321. (d) Waldmeier, P. C.; Tatton, W. G. Interrupting apoptosis in neurodegenerative disease: potential for effective therapy. *Drug Discovery Today* **2004**, *9*, 210–218.
- Wesche-Soldato, D. E.; Swan, R. Z.; Chung, C. S.; Ayala, A. The apoptotic pathway as a therapeutic target in sepsis. *Curr. Drug Targets* **2007**, *8*, 493–500.
- Kim, H. A.; Blanco, F. J. Cell death and apoptosis in osteoarthritic cartilage. *Curr. Drug Targets* **2007**, *8*, 333–345.
- Webster, K. A. Programmed death as a therapeutic target to reduce myocardial infarction. *Trends Pharmacol. Sci.* **2007**, *28*, 492–499.
- Green, A. R.; Shuaib, A. Therapeutic strategies for the treatment of stroke. *Drug Discovery Today* **2006**, *11*, 681–693.
- (a) Daniai, N. N.; Korsmeyer, S. J. Cell death: critical control points. *Cell* **2004**, *116*, 205–219. (b) Kuwana, T.; Newmeyer, D. D. Bcl-2-family proteins and the role of mitochondria in apoptosis. *Curr. Opin. Cell Biol.* **2003**, *15*, 691–699.
- (a) Ashkenazi, A.; Dixit, V. M. Death receptors: signaling and modulation. *Science* **1998**, *281*, 1305–1308. (b) Falschlehner, C.; Emmerich, C. H.; Gerlach, B.; Walczak, H. TRAIL signalling: decisions between life and death. *Int. J. Biochem. Cell Biol.* **2007**, *39*, 1462–1475. (c) Schmitz, I.; Kirchhoff, S.; Krammer, P. H. Regulation of death receptor-mediated apoptosis pathways. *Int. J. Biochem. Cell Biol.* **2000**, *32*, 1123–1136.
- (a) Khosravi-Far, R.; Esposti, M. D. Death receptor signals to mitochondria. *Cancer Biol. Ther.* **2004**, *3*, 1051–1057. (b) Kroemer, G.; Reed, J. C. Mitochondrial control of cell death. *Nat. Med.* **2000**, *6*, 513–519.
- (a) Fischer, U.; Janicke, R. U.; Schulze-Osthoff, K. Many cuts to ruin: a comprehensive update of caspase substrates. *Cell Death Differ.* **2003**, *10*, 76–100. (b) Timmer, J. C.; Salvesen, G. S. Caspase substrates. *Cell Death Differ.* **2007**, *14*, 66–72.
- (a) Cai, S. X.; Guan, L.; Jia, S.; Wang, Y.; Yang, W.; Tseng, B.; Drewe, J. Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: SAR of the N-protecting group. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 5295–5300. (b) Jaeschke, H.; Farhood, A.; Cai, S. X.; Tseng, B. Y.; Bajt, M. L. Protection against TNF-induced liver parenchymal cell apoptosis during endotoxemia by a novel caspase inhibitor in mice. *Toxicol. Appl. Pharmacol.* **2000**, *169*, 77–83.
- (a) Kim, D. S.; Woo, E. R.; Chae, S. W.; Ha, K. C.; Lee, G. H.; Hong, S. T.; Kwon, D. Y.; Kim, M. S.; Jung, Y. K.; Kim, H. M.; Kim, H. K.; Kim, H. R.; Chae, H. J. Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF- $\kappa$ B activation. *Life Sci.* **2007**, *80*, 314–323. (b) Wang, X.; Perez, E.; Liu, R.; Yan, L. J.; Mallet, R. T.; Yang, S. H. Pyruvate protects mitochondria from oxidative stress in human neuroblastoma SK-N-SH cells. *Brain Res.* **2007**, *1132*, 1–9.
- Miller, E. R., 3rd; Pastor-Barriuso, R.; Dalal, D.; Riemersma, R. A.; Appel, L. J.; Guallar, E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann. Intern. Med.* **2005**, *142*, 37–46.
- (a) Donnan, G. A. The 2007 Feinberg lecture: a new road map for neuroprotection. *Stroke* **2008**, *39*, 242–248. (b) Savitz, S. I.; Fisher, M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. *Ann. Neurol.* **2007**, *61*, 396–402.
- Jiang, Z. G.; Lu, X. C.; Nelson, V.; Yang, X.; Pan, W.; Chen, R. W.; Lebowitz, M. S.; Almassian, B.; Tortella, F. C.; Brady, R. O.; Ghanbari, H. A. A multifunctional cytoprotective agent that reduces neurodegeneration after ischemia. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 1581–1586.
- Callus, B. A.; Vaux, D. L. Caspase inhibitors: viral, cellular and chemical. *Cell Death Differ.* **2007**, *14*, 73–78.
- (a) Baskin-Bey, E. S.; Washburn, K.; Feng, S.; Oltersdorf, T.; Shapiro, D.; Huyghe, M.; Burgart, L.; Garrity-Park, M.; van Vilsteren, F. G.; Oliver, L. K.; Rosen, C. B.; Gores, G. J. Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury. *Am. J. Transplant.* **2007**, *7*, 218–225. (b) Linton, S. D. Caspase inhibitors: a pharmaceutical industry perspective. *Curr. Top. Med. Chem.* **2005**, *5*, 1697–1717.
- (a) Kovcsdi, E.; Czeiter, E.; Tamas, A.; Reglodi, D.; Szellar, D.; Pal, J.; Bukovics, P.; Doczi, T.; Buki, A. Rescuing neurons and glia: is inhibition of apoptosis useful? *Prog. Brain Res.* **2007**, *161*, 81–95. (b) Youle, R. J.; Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death. *Nat. Rev. Mol. Cell Biol.* **2008**, *9*, 47–59.
- (a) Chang, L. K.; Putcha, G. V.; Deshmukh, M.; Johnson, E. M., Jr. Mitochondrial involvement in the point of no return in neuronal apoptosis. *Biochimie* **2002**, *84*, 223–231. (b) Keeble, J. A.; Gilmore, A. P. Apoptosis commitment—translating survival signals into decisions on mitochondria. *Cell Res.* **2007**, *17*, 976–984. (c) Kroemer, G. Mitochondrial control of apoptosis: an introduction. *Biochem. Biophys. Res. Commun.* **2003**, *304*, 433–435.
- Lee, H.-J.; Lee, C.-H.; Chung, M.-C.; Chun, H.-K.; Rhee, J.-S.; Kho, Y.-H. Dykellic acid, a novel apoptosis inhibitor from *Westerdykella multispora* F50733. *Tetrahedron Lett.* **1999**, *40*, 6949–6950.
- Heo, J. C.; Park, J. Y.; Woo, S. U.; Rho, J. R.; Lee, H. J.; Kim, S. U.; Kho, Y. H.; Lee, S. H. Dykellic acid inhibits cell migration and tube formation by RhoA-GTP expression. *Biol. Pharm. Bull.* **2006**, *29*, 2256–2259.
- Woo, J. H.; Park, J. W.; Lee, S. H.; Kim, Y. H.; Lee, I. K.; Gabrielson, E.; Lee, S. H.; Lee, H. J.; Kho, Y. H.; Kwon, T. K. Dykellic acid

- inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting nuclear factor kappa B transcriptional activity. *Cancer Res.* **2003**, *63*, 3430–3434.
- (24) Lee, S. H.; Youk, E. S.; Lee, H. J.; Kho, Y. H.; Kim, H. M.; Kim, S. U. Dykellic acid inhibits drug-induced caspase-3-like protease activation. *Biochem. Biophys. Res. Commun.* **2003**, *302*, 539–544.
- (25) (a) Maryanoff, B. E.; Reitz, A. B. The Wittig olefination reaction and modifications involving phosphoryl-stabilized carbanions. Stereochemistry, mechanism, and selected synthetic aspects. *Chem. Rev.* **1989**, *89*, 863–927. (b) Still, W. C.; Gennari, C. Direct synthesis of Z-unsaturated esters. A useful modification of the Horner–Emmons olefination. *Tetrahedron Lett.* **1983**, *24*, 4405–4408.
- (26) Basavaiah, D.; Rao, A. J.; Satyanarayana, T. Recent advances in the Baylis–Hillman reaction and applications. *Chem. Rev.* **2003**, *103*, 811–892.
- (27) Drewes, S. E.; Roos, G. H. P. Synthetic potential of the tertiary-amine-catalysed reaction of activated vinyl carbanions with aldehydes. *Tetrahedron* **1988**, *44*, 4653–4670.
- (28) Hoffmann, H. M. R.; Rabe, J. Preparation of 2-(1-hydroxyalkyl)acrylic esters; simple three-step synthesis of mikancic acid. *Angew. Chem., Int. Ed. Engl.* **1983**, *22*, 795–796.
- (29) (a) Faltin, C.; Fleming, E. M.; Connon, S. J. Acrylamide in the Baylis–Hillman reaction: expanded reaction scope and the unexpected superiority of DABCO over more basic tertiary amine catalysts. *J. Org. Chem.* **2004**, *69*, 6496–6499. (b) Wei, G.; Weiwei, W.; Ningjuan, F.; Zhengang, W.; Chizhong, X. Synthesis of alpha-substituted N-aryl acrylamide derivatives through Baylis–Hillman reaction. *Synth. Commun.* **2005**, *35*, 1239–1251.
- (30) Singh, V.; Yadav, G. P.; Maulik, P. R.; Batra, S. Synthesis of substituted 3-methylene-2-pyridones from Baylis–Hillman derivatives and its application for the generation of 2-pyridone substituted spiroisoxazolines. *Tetrahedron* **2008**, *64*, 2979–2991.
- (31) (a) Arecas, P. C.; Carrasco, E.; Mancha, A.; Plumet, J. Tandem  $\beta$ -elimination–Morita–Baylis–Hillman reaction in  $\alpha,\beta$ -unsaturated sugar aldehydes. *Synthesis* **2006**, *6*, 946–948. (b) Drewes, S. E.; Emslie, N. D.; Khan, A. A.; Roos, G. H. P. 1,2-Addition of activated vinyl carbanions to  $\beta$ -unsaturated carbonyls. *Synth. Commun.* **1989**, *19*, 959–964. (c) Heerden, F. R. v.; Huysen, J. J.; Holzapfel, C. W. Preparation of multifunctional stereodefined dienes. *Synth. Commun.* **1994**, *24*, 2863–2872. (d) Hsu, J.-C.; Yen, Y.-H.; Chu, Y.-H. Baylis–Hillman reaction in [bdmim][PF<sub>6</sub>] ionic liquid. *Tetrahedron Lett.* **2004**, *45*, 4673–4676.
- (32) Zapf, C. W.; Harrison, B. A.; Drahl, C.; Sorensen, E. J. A Diels–Alder macrocyclization enables an efficient asymmetric synthesis of the antibacterial natural product abyssomicin C. *Angew. Chem., Int. Ed.* **2005**, *44*, 6533–6537.
- (33) Williams, C. M.; Mander, L. N. Chromatography with silver nitrate. *Tetrahedron* **2001**, *57*, 425–447.
- (34) Dess, D. B.; Martin, J. C. Readily accessible 12-I-5 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones. *J. Org. Chem.* **1983**, *43*, 4155–4156.
- (35) Bal, B. S.; Childers, W. E.; Pinnick, H. W. Oxidation of [alpha],[beta]-unsaturated aldehydes. *Tetrahedron* **1981**, *37*, 2091–2096.
- (36) Demidenko, Z. N.; Vivo, C.; Halicka, H. D.; Li, C. J.; Bhalla, K.; Broude, E. V.; Blagosklonny, M. V. Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection. *Cell Death Differ.* **2006**, *13*, 1434–1441.
- (37) Kanupriya; Prasad, D.; Ram, M. S.; Kumar, R.; Sawhney, R. C.; Sharma, S. K.; Ilavazhagan, G.; Kumar, D.; Banerjee, P. K. Cytoprotective and antioxidant activity of *Rhodiola imbricata* against tert-butyl hydroperoxide induced oxidative injury in U-937 human macrophages. *Mol. Cell. Biochem.* **2005**, *275*, 1–6.
- (38) (a) Sestili, P.; Martinelli, C.; Bravi, G.; Piccoli, G.; Curci, R.; Battistelli, M.; Falcieri, E.; Agostini, D.; Gioacchini, A. M.; Stocchi, V. Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. *Free Radical Biol. Med.* **2006**, *40*, 837–849. (b) Young, J.; Wahle, K. W.; Boyle, S. P. Cytoprotective effects of phenolic antioxidants and essential fatty acids in human blood monocyte and neuroblastoma cell lines: surrogates for neurological damage in vivo. *Prostaglandins, Leukotrienes Essent. Fatty Acids* **2008**, *78*, 45–59.
- (39) Lee, J.; Huang, M. S.; Yang, I. C.; Lai, T. C.; Wang, J. L.; Pang, V. F.; Hsiao, M.; Kuo, M. Y. Essential roles of caspases and their upstream regulators in rotenone-induced apoptosis. *Biochem. Biophys. Res. Commun.* **2008**, *371*, 33–38.
- (40) (a) Egea, J.; Rosa, A. O.; Cuadrado, A.; Garcia, A. G.; Lopez, M. G. Nicotinic receptor activation by epibatidine induces heme oxygenase-1 and protects chromaffin cells against oxidative stress. *J. Neurochem.* **2007**, *102*, 1842–1852. (b) Imamura, K.; Takeshima, T.; Kashiwaya, Y.; Nakaso, K.; Nakashima, K. D-beta-Hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease. *J. Neurosci. Res.* **2006**, *84*, 1376–1384. (c) Molina-Jimenez, M. F.; Sanchez-Reus, M. I.; Andres, D.; Cascales, M.; Benedi, J. Neuroprotective effect of fraxetin and myricetin against rotenone-induced apoptosis in neuroblastoma cells. *Brain Res.* **2004**, *1009*, 9–16.
- (41) (a) Kapiszewska, M.; Cierniak, A.; Elas, M.; Lankoff, A. Lifespan of etoposide-treated human neutrophils is affected by antioxidant ability of quercetin. *Toxicol. in Vitro* **2007**, *21*, 1020–1030. (b) Rusovici, R.; Ghaleb, A.; Shim, H.; Yang, V. W.; Yun, C. C. Lysophosphatidic acid prevents apoptosis of Caco-2 colon cancer cells via activation of mitogen-activated protein kinase and phosphorylation of Bad. *Biochim Biophys Acta* **2007**, *1770*, 1194–1203. (c) Salido, M.; Gonzalez, J. L.; Vilches, J. Loss of mitochondrial membrane potential is inhibited by bombesin in etoposide-induced apoptosis in PC-3 prostate carcinoma cells. *Mol. Cancer Ther.* **2007**, *6*, 1292–1299.
- (42) (a) Bechoua, S.; Dubois, M.; Dominguez, Z.; Goncalves, A.; Nemoz, G.; Lagarde, M.; Prigent, A. F. Protective effect of docosahexaenoic acid against hydrogen peroxide-induced oxidative stress in human lymphocytes. *Biochem. Pharmacol.* **1999**, *57*, 1021–1030. (b) Fatokun, A. A.; Stone, T. W.; Smith, R. A. Hydrogen peroxide-induced oxidative stress in MC3T3-E1 cells: the effects of glutamate and protection by purines. *Bone* **2006**, *39*, 542–551.
- (43) Lee, M. W.; Kim, W. J.; Beardsley, D. I.; Brown, K. D. N-Methyl-N-nitroso-guanidine activates multiple cell death mechanisms in human fibroblasts. *DNA Cell Biol.* **2007**, *26*, 683–694.
- (44) Yu, S. W.; Wang, H.; Poitras, M. F.; Coombs, C.; Bowers, W. J.; Federoff, H. J.; Poirier, G. G.; Dawson, T. M.; Dawson, V. L. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. *Science* **2002**, *297*, 259–263.
- (45) (a) Hengartner, M. O. The biochemistry of apoptosis. *Nature* **2000**, *407*, 770–776. (b) Taylor, R. C.; Cullen, S. P.; Martin, S. J. Apoptosis: controlled demolition at the cellular level. *Nat. Rev. Mol. Cell Biol.* **2008**, *9*, 231–241.
- (46) (a) Riedl, S. J.; Shi, Y. Molecular mechanisms of caspase regulation during apoptosis. *Nat. Rev. Mol. Cell Biol.* **2004**, *5*, 897–907. (b) Stennicke, H. R.; Jurgensmeier, J. M.; Shin, H.; Deveraux, Q.; Wolf, B. B.; Yang, X.; Zhou, Q.; Ellerby, H. M.; Ellerby, L. M.; Bredesen, D.; Green, D. R.; Reed, J. C.; Froelich, C. J.; Salvesen, G. S. Procaspase-3 is a major physiologic target of caspase-8. *J. Biol. Chem.* **1998**, *273*, 27084–27090.
- (47) (a) Benjamin, C. W.; Hiesch, R. R.; Jones, D. A. Caspase activation in MCF7 cells responding to etoposide treatment. *Mol. Pharmacol.* **1998**, *53*, 446–450. (b) Kim, Y. M.; Chung, H. T.; Kim, S. S.; Han, J. A.; Yoo, Y. M.; Kim, K. M.; Lee, G. H.; Yun, H. Y.; Green, A.; Li, J.; Simmons, R. L.; Billiar, T. R. Nitric oxide protects PC12 cells from serum deprivation-induced apoptosis by cGMP-dependent inhibition of caspase signaling. *J. Neurosci.* **1999**, *19*, 6740–6747.
- (48) (a) Goode, D. R.; Sharma, A. K.; Hergenrother, P. J. Using peptidic inhibitors to systematically probe the S1' site of caspase-3 and caspase-7. *Org. Lett.* **2005**, *7*, 3529–3532. (b) Micale, N.; Vairagoundar, R.; Yakovlev, A. G.; Kozikowski, A. P. Design and synthesis of a potent and selective peptidomimetic inhibitor of caspase-3. *J. Med. Chem.* **2004**, *47*, 6455–6458. (c) Yoshimori, A.; Sakai, J.; Sunaga, S.; Kobayashi, T.; Takahashi, S.; Okita, N.; Takasawa, R.; Tanuma, S. Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO. *BMC Pharmacol.* **2007**, *7*, 8.
- (49) (a) Choong, I. C.; Lew, W.; Lee, D.; Pham, P.; Burdett, M. T.; Lam, J. W.; Wiesmann, C.; Luong, T. N.; Fahr, B.; DeLano, W. L.; McDowell, R. S.; Allen, D. A.; Erlanson, D. A.; Gordon, E. M.; O'Brien, T. Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design. *J. Med. Chem.* **2002**, *45*, 5005–5022. (b) Chu, W.; Rothfuss, J.; d'Avignon, A.; Zeng, C.; Zhou, D.; Hotchkiss, R. S.; Mach, R. H. Isatin sulfonamide analogs containing a Michael addition acceptor: a new class of caspase 3/7 inhibitors. *J. Med. Chem.* **2007**, *50*, 3751–3755. (c) Kravchenko, D. V.; Kuzovkova, Y. A.; Kysil, V. M.; Tkachenko, S. E.; Maliarchouk, S.; Okun, I. M.; Balakin, K. V.; Ivachchenko, A. V. Synthesis and structure–activity relationship of 4-substituted 2-(2-acetyloxyethyl)-8-(morpholine-4-sulfonyl)pyrrolo[3,4-c]quinoline-1,3-diones as potent caspase-3 inhibitors. *J. Med. Chem.* **2005**, *48*, 3680–3683.
- (50) (a) Smith, G. K.; Barrett, D. G.; Blackburn, K.; Cory, M.; Dallas, W. S.; Davis, R.; Hassler, D.; McConnell, R.; Moyer, M.; Weaver, K. Expression, preparation, and high-throughput screening of caspase-8: discovery of redox-based and steroid diacid inhibition. *Arch. Biochem. Biophys.* **2002**, *399*, 195–205. (b) Talanian, R. V.; Quinlan, C.; Trautz, S.; Hackett, M. C.; Mankovich, J. A.; Banach, D.; Ghayur, T.; Brady, K. D.; Wong, W. W. Substrate specificities of caspase family proteases. *J. Biol. Chem.* **1997**, *272*, 9677–9682.
- (51) (a) Gomes, A.; Fernandes, E.; Lima, J. L. Fluorescence probes used for detection of reactive oxygen species. *J. Biochem. Biophys. Methods* **2005**, *65*, 45–80. (b) Li, L.; Jiang, L.; Geng, C.; Cao, J.; Zhong, L. The role of oxidative stress in acrolein-induced DNA damage in

- HepG2 cells. *Free Radical Res.* **2008**, *42*, 354–361. (c) Vowells, S. J.; Sekhsaria, S.; Malech, H. L.; Shalit, M.; Fleisher, T. A. Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. *J. Immunol. Methods* **1995**, *178*, 89–97.
- (52) (a) Bindokas, V. P.; Jordan, J.; Lee, C. C.; Miller, R. J. Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine. *J. Neurosci.* **1996**, *16*, 1324–1336. (b) D'Agostino, D. P.; Putnam, R. W.; Dean, J. B. Superoxide ( $\text{O}_2^-$ ) production in CA1 neurons of rat hippocampal slices exposed to graded levels of oxygen. *J. Neurophysiol.* **2007**, *98*, 1030–1041. (c) Shimoni, Y.; Chen, K.; Emmett, T.; Kargacin, G. Aldosterone and the autocrine modulation of potassium currents and oxidative stress in the diabetic rat heart. *Br. J. Pharmacol.* **2008**, *154*, 675–687.
- (53) Traber, M. G.; Atkinson, J. Vitamin E, antioxidant and nothing more. *Free Radical Biol. Med.* **2007**, *43*, 4–15.
- (54) Zhang, S.; Lin, Y.; Kim, Y. S.; Hande, M. P.; Liu, Z. G.; Shea, H. M. c-Jun N-terminal kinase mediates hydrogen peroxide-induced cell death via sustained poly(ADP-ribose) polymerase-1 activation. *Cell Death Differ.* **2007**, *14*, 1001–1010.
- (55) Bromberg, K. D.; Burgin, A. B.; Osheroff, N. A two-drug model for etoposide action against human topoisomerase II $\alpha$ . *J. Biol. Chem.* **2003**, *278*, 7406–7412.
- (56) Hande, K. R. Topoisomerase II inhibitors. *Update Cancer Ther.* **2006**, *1*, 3–15.
- (57) Sherer, T. B.; Betarbet, R.; Testa, C. M.; Seo, B. B.; Richardson, J. R.; Kim, J. H.; Miller, G. W.; Yagi, T.; Matsuno-Yagi, A.; Greenamyre, J. T. Mechanism of toxicity in rotenone models of Parkinson's disease. *J. Neurosci.* **2003**, *23*, 10756–10764.
- (58) Bai, P.; Hegedus, C.; Erdelyi, K.; Szabo, E.; Bakondi, E.; Gergely, S.; Szabo, C.; Virag, L. Protein tyrosine nitration and poly(ADP-ribose) polymerase activation in *N*-methyl-*N*-nitro-*N*-nitrosoguanidine-treated thymocytes: implication for cytotoxicity. *Toxicol. Lett.* **2007**, *170*, 203–213.
- (59) Andrabi, S. A.; Kim, N. S.; Yu, S. W.; Wang, H.; Koh, D. W.; Sasaki, M.; Klaus, J. A.; Otsuka, T.; Zhang, Z.; Koehler, R. C.; Hurn, P. D.; Poirier, G. G.; Dawson, V. L.; Dawson, T. M. Poly(ADP-ribose) (PAR) polymer is a death signal. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 18308–18313.
- (60) (a) Heeres, J. T.; Hergenrother, P. J. Poly(ADP-ribose) makes a date with death. *Curr. Opin. Chem. Biol.* **2007**, *11*, 644–653. (b) Moubarak, R. S.; Yuste, V. J.; Artus, C.; Bouharrou, A.; Greer, P. A.; Menissier-de Murcia, J.; Susin, S. A. Sequential activation of poly(ADP-ribose) polymerase 1, calpains, and Bax is essential in apoptosis-inducing factor-mediated programmed necrosis. *Mol. Cell. Biol.* **2007**, *27*, 4844–4862.
- (61) Sestili, P.; Martinelli, C.; Bravi, G.; Piccoli, G.; Curci, R.; Battistelli, M.; Falcieri, E.; Agostini, D.; Gioacchini, A. M.; Stocchi, V. Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. *Free Radical Biol. Med.* **2006**, *40*, 837–849.
- (62) Riordan, F. A.; Bravery, C. A.; Mengubas, K.; Ray, N.; Borthwick, N. J.; Akbar, A. N.; Hart, S. M.; Hoffbrand, A. V.; Mehta, A. B.; Wickremasinghe, R. G. Herbimycin A accelerates the induction of apoptosis following etoposide treatment or gamma-irradiation of bcr/abl-positive leukaemia cells. *Oncogene* **1998**, *16*, 1533–1542.
- (63) (a) Chiarugi, A. Poly(ADP-ribosylation) and stroke. *Pharmacol. Res.* **2005**, *52*, 15–24. (b) Fossati, S.; Cipriani, G.; Moroni, F.; Chiarugi, A. Neither energy collapse nor transcription underlie in vitro neurotoxicity of poly(ADP-ribose) polymerase hyper-activation. *Neurochem. Int.* **2007**, *50*, 203–210. (c) Moroni, F. Poly(ADP-ribose) polymerase 1 (PARP-1) and postischemic brain damage. *Curr. Opin. Pharmacol.* **2008**, *8*, 96–103.
- (64) (a) Cho, J.-H.; Ko, S. Y. Synthesis and MMP-inhibitory activity of gelastatin analogues. *Helv. Chim. Acta* **2002**, *85*, 3994–3999. (b) Chun, K.; Park, S. K.; Kim, H. M.; Choi, Y.; Kim, M. H.; Park, C. H.; Joe, B. Y.; Chun, T. G.; Choi, H. M.; Lee, H. Y.; Hong, S. H.; Kim, M. S.; Nam, K. Y.; Han, G. Chromen-based TNF- $\alpha$  converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. *Bioorg. Med. Chem.* **2008**, *16*, 530–535. (c) Kim, E. J.; Ko, S. Y. Synthesis of arylidene-substituted gelastatin analogues and their screening for MMP-2 inhibitory activity. *Bioorg. Med. Chem.* **2005**, *13*, 4103–4112. (d) Lee, H. J.; Chung, M. C.; Lee, C. H.; Chun, H. K.; Rhee, J. S.; Kho, Y. H. Gelastatins, new inhibitors of matrix metalloproteinases from *Westerdykella multispora* F50733. *Ann. N.Y. Acad. Sci.* **1999**, *878*, 635–637. (e) Park, S. K.; Han, S. B.; Lee, K.; Lee, H. J.; Kho, Y. H.; Chun, H.; Choi, Y.; Yang, J. Y.; Yoon, Y. D.; Lee, C. W.; Kim, H. M.; Choi, H. M.; Tae, H. S.; Lee, H. Y.; Nam, K. Y.; Han, G. Gelastatins and their hydroxamates as dual functional inhibitors for TNF- $\alpha$  converting enzyme and matrix metalloproteinases: synthesis, biological evaluation, and mechanism studies. *Biochem. Biophys. Res. Commun.* **2006**, *341*, 627–634.